AAOS: GLP-1 receptor agonist use increases five-year risk for osteoporosis

Treatment with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for type 2 diabetes and obesity is independently associated with a significantly increased five-year risk for osteoporosis, gout, and osteomalacia compared with nonuse, according to a study presented at the annual meeting of the American Academy of Orthopaedic Surgeons, held from March 2 to 6 in New Orleans.

source https://medicalxpress.com/news/2026-03-aaos-glp-receptor-agonist-year.html